<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">HET</journal-id>
<journal-id journal-id-type="hwp">sphet</journal-id>
<journal-id journal-id-type="nlm-ta">Hum Exp Toxicol</journal-id>
<journal-title>Human &amp; Experimental Toxicology</journal-title>
<issn pub-type="ppub">0960-3271</issn>
<issn pub-type="epub">1477-0903</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage UK: London, England</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/0960327112450897</article-id>
<article-id pub-id-type="publisher-id">10.1177_0960327112450897</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Original Papers</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Prophylactic 0.9% saline hydration inhibited high-dose gadodiamide-induced nephropathy in rats</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Chien</surname>
<given-names>C-C</given-names>
</name>
<xref ref-type="aff" rid="aff1-0960327112450897">1</xref>
<xref ref-type="aff" rid="aff2-0960327112450897">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Sheu</surname>
<given-names>M-J</given-names>
</name>
<xref ref-type="aff" rid="aff3-0960327112450897">3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Chu</surname>
<given-names>C-C</given-names>
</name>
<xref ref-type="aff" rid="aff4-0960327112450897">4</xref>
<xref ref-type="aff" rid="aff5-0960327112450897">5</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Sun</surname>
<given-names>Y-M</given-names>
</name>
<xref ref-type="aff" rid="aff6-0960327112450897">6</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Kan</surname>
<given-names>W-C</given-names>
</name>
<xref ref-type="aff" rid="aff1-0960327112450897">1</xref>
<xref ref-type="aff" rid="aff7-0960327112450897">7</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Wang</surname>
<given-names>H-Y</given-names>
</name>
<xref ref-type="aff" rid="aff1-0960327112450897">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Hwang</surname>
<given-names>J-C</given-names>
</name>
<xref ref-type="aff" rid="aff1-0960327112450897">1</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Wang</surname>
<given-names>J-J</given-names>
</name>
<xref ref-type="aff" rid="aff8-0960327112450897">8</xref>
<xref ref-type="corresp" rid="corresp1-0960327112450897"/>
</contrib>
<aff id="aff1-0960327112450897">
<label>1</label>Department of Nephrology, Chi-Mei Medical Center, Tainan, Taiwan</aff>
<aff id="aff2-0960327112450897">
<label>2</label>Department of Food Nutrition, Chung Hwa University of Medical Technology, Tainan, Taiwan</aff>
<aff id="aff3-0960327112450897">
<label>3</label>Department of Gastroenterology, Chi-Mei Medical Center, Tainan, Taiwan</aff>
<aff id="aff4-0960327112450897">
<label>4</label>Departments of Anesthesiology, Chi-Mei Medical Center, Tainan, Taiwan</aff>
<aff id="aff5-0960327112450897">
<label>5</label>Department of Recreation and Health-Care Management, Chia Nan University of Pharmacy &amp; Science, Tainan, Taiwan</aff>
<aff id="aff6-0960327112450897">
<label>6</label>Department of Occupational Safety and Health, Chung Hwa University of Medical Technology, Tainan, Taiwan</aff>
<aff id="aff7-0960327112450897">
<label>7</label>Department of Medical Laboratory Science and Biotechnology, Chung Hwa University of Medical Technology, Tainan, Taiwan</aff>
<aff id="aff8-0960327112450897">
<label>8</label>Department of Medical Research Chi-Mei Medical Center, Tainan, Taiwan</aff>
</contrib-group>
<author-notes>
<corresp id="corresp1-0960327112450897">J-J Wang, Department of Medical Research, Chi-Mei Medical Center, 901 Jung-Hua Road, Yung Kang City, Tainan 710, Taiwan Email: <email>400002@mail.chimei.org.tw</email>
</corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>11</month>
<year>2012</year>
</pub-date>
<volume>31</volume>
<issue>11</issue>
<fpage>1170</fpage>
<lpage>1178</lpage>
<permissions>
<copyright-statement>© The Author(s) 2012</copyright-statement>
<copyright-year>2012</copyright-year>
<copyright-holder content-type="sage">SAGE Publications</copyright-holder>
</permissions>
<abstract>
<p>High doses of gadolinium-based contrast media are reported to induce deterioration of renal function. We assessed whether prophylactic 0.9% saline hydration inhibits high-dose gadodiamide-induced renal damage in rats. Twelve Sprague-Dawley rats were randomly divided into two groups, which are given gadodiamide (5 mmol/kg) with (hydration group) or without (control group) 0.9% saline hydration. The saline (4 mL/kg) was infused as a bolus into the peritoneum every 4 h, starting 12 h before and continuing for 12 h after the gadodiamide injection. Urine was collected to calculate creatinine clearance (Ccr) 24 h before and 48 h after the gadodiamide injection. The kidneys were harvested and stained for pathologic analysis. High-dose gadodiamide induced acute kidney injury as shown by decreased Ccr and renal histology with tubular cell injuries 48 h postinjection in both the groups. However, the extent of Ccr reduction was significantly (<italic>p</italic> = 0.02) less in the hydrated rats (−15% in the hydration group vs. −39% in the control group). Renal tubular cell injuries characterized by vacuolization, loss of brush borders, sloughing of tubular cells into the lumen, and flattening of the tubular epithelium were less frequently seen in the hydration group; only vacuolization (<italic>p</italic> = 0.01) and epithelial sloughing (<italic>p</italic> = 0.02) of the proximal tubules differed significantly between the two groups. We conclude that prophylactic 0.9% saline hydration significantly inhibited high-dose gadodiamide-induced nephropathy.</p>
</abstract>
<kwd-group>
<kwd>Gadolinium-based contrast media</kwd>
<kwd>acute kidney injury</kwd>
<kwd>hydration</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="section1-0960327112450897">
<title>Introduction</title>
<p>Contrast medium (CM)-induced nephropathy (CIN) is a serious complication of radiological examinations that require iodinated CM in high-risk patients.<sup>
<xref ref-type="bibr" rid="bibr1-0960327112450897">1</xref>,<xref ref-type="bibr" rid="bibr2-0960327112450897">2</xref>
</sup> CIN is the third most common cause of acute kidney injury in hospitalized patients.<sup>
<xref ref-type="bibr" rid="bibr3-0960327112450897">3</xref>
</sup> Gadolinium-based CM (Gd-CM) was developed for magnetic resonance imaging (MRI) and considered non-nephrotoxic.<sup>
<xref ref-type="bibr" rid="bibr4-0960327112450897">4</xref>
<xref ref-type="bibr" rid="bibr5-0960327112450897"/>
<xref ref-type="bibr" rid="bibr6-0960327112450897"/>–<xref ref-type="bibr" rid="bibr7-0960327112450897">7</xref>
</sup> However, increasing evidence has shown a close association between Gd-CM and CIN.<sup>
<xref ref-type="bibr" rid="bibr8-0960327112450897">8</xref>
<xref ref-type="bibr" rid="bibr9-0960327112450897"/>
<xref ref-type="bibr" rid="bibr10-0960327112450897"/>
<xref ref-type="bibr" rid="bibr11-0960327112450897"/>
<xref ref-type="bibr" rid="bibr12-0960327112450897"/>
<xref ref-type="bibr" rid="bibr13-0960327112450897"/>
<xref ref-type="bibr" rid="bibr14-0960327112450897"/>
<xref ref-type="bibr" rid="bibr15-0960327112450897"/>
<xref ref-type="bibr" rid="bibr16-0960327112450897"/>
<xref ref-type="bibr" rid="bibr17-0960327112450897"/>
<xref ref-type="bibr" rid="bibr18-0960327112450897"/>
<xref ref-type="bibr" rid="bibr19-0960327112450897"/>
<xref ref-type="bibr" rid="bibr20-0960327112450897"/>–<xref ref-type="bibr" rid="bibr21-0960327112450897">21</xref>
</sup>
</p>
<p>At the cellular level, when cultured renal tubular cells are incubated with Gd-CM or iodinated CM, the cytotoxic effects, referred to as the extent of necrosis and apoptosis, are similar.<sup>
<xref ref-type="bibr" rid="bibr22-0960327112450897">22</xref>
</sup> Moreover, Gd-CM agents are even more nephrotoxic than iodinated CM when administered intra-arterially at equimolar doses in pigs.<sup>
<xref ref-type="bibr" rid="bibr9-0960327112450897">9</xref>
</sup> Human studies<sup>
<xref ref-type="bibr" rid="bibr17-0960327112450897">17</xref>,<xref ref-type="bibr" rid="bibr19-0960327112450897">19</xref>
</sup> also report that Gd may be nephrotoxic. Clinical reports revealed a 3.5%–12% incidence of acute kidney injury associated with Gd-CM in a high-risk population with underlying renal dysfunction. In addition, the incidence of deterioration of renal function is even higher in patients who undergo digital subtraction angiography requiring high intra-arterial doses of Gd-CM.<sup>
<xref ref-type="bibr" rid="bibr8-0960327112450897">8</xref>,<xref ref-type="bibr" rid="bibr23-0960327112450897">23</xref>,<xref ref-type="bibr" rid="bibr24-0960327112450897">24</xref>
</sup> The clinically recommended dose of gadodiamide is between 0.1 and 0.3 mmol/kg for an MRI examination, while in digital subtraction angiography, high intra-arterial doses (up to 220 mmol) are required, which can cause a high incidence of nephropathy.<sup>
<xref ref-type="bibr" rid="bibr1-0960327112450897">1</xref>
</sup> It is known that the prophylactic hydration therapy effectively inhibits iodinated CM-induced nephropathy.<sup>
<xref ref-type="bibr" rid="bibr2-0960327112450897">2</xref>
</sup> However, whether prophylactic saline hydration also inhibits high-dose gadodiamide-induced nephropathy has never been evaluated. Therefore, we assessed whether prophylactic 0.9% saline hydration inhibits high-dose gadodiamide-induced renal damage in a rat model.</p>
</sec>
<sec id="section2-0960327112450897" sec-type="methods">
<title>Methods</title>
<sec id="section3-0960327112450897">
<title>Animals</title>
<p>Male adult Sprague-Dawley rats (weighing 250–300 g), obtained from the Animal Resource Center of the National Science Council of Taiwan, were housed at an ambient temperature of 22 ± 1°C with a 12-h light/dark cycle. Pellet rat chow and tap water were available ad libitum. All protocols were approved by the Animal Ethics Committee of the Chi-Mei Medical Center in accordance with the Guide for the Care and Use of Laboratory Animals of the USA National Institutes of Health and the guidelines of the USA Animal Welfare Act.</p>
</sec>
<sec id="section4-0960327112450897">
<title>Inducing renal damage</title>
<p>After they had been intraperitoneally (i.p.) injected with an anesthetic (tiletamine hypochloride/zolazepam hypochloride (Zoletil; Virbac Laboratories, Carros, France); 5.0–7.5 mg/100 g BW), the rats underwent venous cannulation via the right femoral vein with PE-50 polyethylene tubes. Twelve rats were then randomly assigned to the hydration group (infused with gadodiamide (5 mmol/kg) and i.p. injected with saline (0.9% NaCl; 4 mL/kg; every 4 h from 12 h before to 12 h after the gadodiamide infusion)) or the control group (infused with gadodiamide (5 mmol/kg); <italic>n</italic> = 6 for each group). Although the suggested clinical dose of gadodiamide is around 0.1–0.3 mmol/kg for MRI, a higher dose (0.4 mmol/kg) was used for digital subtraction angiography. A single 5-mmol/kg gadodiamide injection in rats produced acute nephrotoxicity with moderate pathological change<sup>
<xref ref-type="bibr" rid="bibr25-0960327112450897">25</xref>,<xref ref-type="bibr" rid="bibr26-0960327112450897">26</xref>
</sup>; therefore, for this study, we chose the higher dose of 5 mmol/kg. The gadodiamide (Omniscan; GE Healthcare Life Sciences, Taipei, Taiwan; 0.5 mol/L; osmolarity = 0.78 osm/kg) was slowly infused over a 5-min interval through indwelling femoral vein catheters in both the groups.</p>
</sec>
<sec id="section5-0960327112450897">
<title>Evaluating renal function</title>
<p>Blood samples were withdrawn from the tail veins of each untreated rat to measure serum creatinine (SCr) (Jaffe reaction Creatinine kit; Wako Pure Chemical Industries, Osaka, Japan). The rats were then put into individual metabolic cages and their 24-h urine sample was collected to measure baseline urinary creatinine (UCr). The next day, the rats underwent femoral vein catheterization and were infused with gadodiamide, after which they were put into the metabolic cages to obtain a second 24-h urine sample after the gadodiamide (24–48 h after the gadodiamide infusion) infusion to measure posttreatment UCr. A second blood sample from the tail vein was obtained 48 h after the gadodiamide infusion to measure posttreatment SCr. Creatinine clearance (Ccr) was calculated using the following formula
<disp-formula id="disp-formula1-0960327112450897">
<mml:math id="mml-disp1-0960327112450897">
<mml:mrow><mml:mtext>Ccr</mml:mtext><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mtext>mL/</mml:mtext><mml:mi>min</mml:mi><mml:mo>⁡</mml:mo></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mo>=</mml:mo><mml:mrow><mml:mo>[</mml:mo> <mml:mrow><mml:mtext>UCr/SCr</mml:mtext></mml:mrow> <mml:mo>]</mml:mo></mml:mrow><mml:mo>×</mml:mo><mml:mrow><mml:mo>[</mml:mo><mml:mrow><mml:mrow><mml:mrow><mml:mtext>urine</mml:mtext><mml:mo> </mml:mo><mml:mtext>volume</mml:mtext><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mtext>mL</mml:mtext></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow><mml:mo>/</mml:mo><mml:mrow><mml:mn>1440</mml:mn></mml:mrow></mml:mrow></mml:mrow> <mml:mo>]</mml:mo></mml:mrow></mml:mrow>
</mml:math>
<graphic alternate-form-of="disp-formula1-0960327112450897" xlink:href="10.1177_0960327112450897-eq1.tif"/>
</disp-formula>
Gadodiamide-induced nephropathy was defined as a significant reduction in Ccr relative to the baseline value after the rat had been exposed to the CM. The percentage change in Ccr was calculated as follows
<disp-formula id="disp-formula2-0960327112450897">
<mml:math id="mml-disp2-0960327112450897">
<mml:mrow><mml:mi>%</mml:mi><mml:mo> </mml:mo><mml:mtext>Change</mml:mtext><mml:mo>=</mml:mo><mml:mrow><mml:mrow><mml:mrow><mml:mo>[</mml:mo><mml:mrow><mml:mtext>Ccr</mml:mtext><mml:mo> </mml:mo><mml:mtext>at</mml:mtext><mml:mo> </mml:mo><mml:mtext>48</mml:mtext><mml:mo> </mml:mo><mml:mtext>h</mml:mtext><mml:mo> </mml:mo><mml:mtext>after</mml:mtext><mml:mo> </mml:mo><mml:mtext>Gd-CM</mml:mtext><mml:mo>−</mml:mo><mml:mtext>baseline</mml:mtext><mml:mo> </mml:mo><mml:mtext>Ccr</mml:mtext></mml:mrow> <mml:mo>]</mml:mo></mml:mrow></mml:mrow><mml:mo>/</mml:mo><mml:mrow><mml:mrow><mml:mo>[</mml:mo> <mml:mrow><mml:mtext>Baseline</mml:mtext><mml:mo> </mml:mo><mml:mtext>Ccr</mml:mtext></mml:mrow> <mml:mo>]</mml:mo></mml:mrow></mml:mrow></mml:mrow></mml:mrow>
</mml:math>
<graphic alternate-form-of="disp-formula2-0960327112450897" xlink:href="10.1177_0960327112450897-eq2.tif"/>
</disp-formula>
</p>
</sec>
<sec id="section6-0960327112450897">
<title>Evaluating morphological damage</title>
<p>To assess pathological damage to the kidney, at the end of the experiments (48 h after the gadodiamide infusion), the rats were given a lethal overdose of ethyl carbamate. Their kidneys were removed and perfused with 10% neutral-buffered formalin and then embedded in paraffin blocks. The blocks were serially sliced into 5-μm-thick sections and then stained with hematoxylin and eosin.</p>
<p>The sections were evaluated by a nephropathologist blinded to the treatment. The morphological changes indicating acute tubular necrosis of 100 randomly selected proximal collecting tubules (<italic>n</italic> = 100, for each group) included cytoplasmic vacuolization, epithelial sloughing, and epithelial thinning. These characteristics were semiquantitatively scored on a scale of 0–2 (<xref ref-type="table" rid="table1-0960327112450897">Table 1</xref>). The scores for each group were weighted as follows
<disp-formula id="disp-formula3-0960327112450897">
<mml:math id="mml-disp3-0960327112450897">
<mml:mrow><mml:mtext>Weighted</mml:mtext><mml:mo> </mml:mo><mml:mtext>score</mml:mtext><mml:mo>=</mml:mo><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mn>0</mml:mn><mml:mo>×</mml:mo><mml:mrow><mml:mo>[</mml:mo> <mml:mrow><mml:mtext>number</mml:mtext><mml:mo> </mml:mo><mml:mtext>of</mml:mtext><mml:mo> </mml:mo><mml:mtext>cells</mml:mtext><mml:mo> </mml:mo><mml:mtext>scored</mml:mtext><mml:mo> </mml:mo><mml:mn>0</mml:mn></mml:mrow> <mml:mo>]</mml:mo></mml:mrow></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mo>+</mml:mo><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mn>1</mml:mn><mml:mo>×</mml:mo><mml:mrow><mml:mo>[</mml:mo> <mml:mrow><mml:mtext>number</mml:mtext><mml:mo> </mml:mo><mml:mtext>of</mml:mtext><mml:mo> </mml:mo><mml:mtext>cells</mml:mtext><mml:mo> </mml:mo><mml:mtext>scored</mml:mtext><mml:mo> </mml:mo><mml:mn>1</mml:mn></mml:mrow> <mml:mo>]</mml:mo></mml:mrow></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mo>+</mml:mo><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mn>2</mml:mn><mml:mo>×</mml:mo><mml:mrow><mml:mo>[</mml:mo> <mml:mrow><mml:mtext>number</mml:mtext><mml:mo> </mml:mo><mml:mtext>of</mml:mtext><mml:mo> </mml:mo><mml:mtext>cells</mml:mtext><mml:mo> </mml:mo><mml:mtext>scored</mml:mtext><mml:mo> </mml:mo><mml:mn>2</mml:mn></mml:mrow><mml:mo>]</mml:mo></mml:mrow></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow>
</mml:math>
<graphic alternate-form-of="disp-formula3-0960327112450897" xlink:href="10.1177_0960327112450897-eq3.tif"/>
</disp-formula></p>
<table-wrap id="table1-0960327112450897" position="float">
<label>Table 1.</label>
<caption>
<p>Renal PT damage scores</p>
</caption>
<graphic alternate-form-of="table1-0960327112450897" xlink:href="10.1177_0960327112450897-table1.tif"/>
<table>
<thead>
<tr>
<th>
</th>
<th>Score</th>
<th>Pathological finding</th>
</tr>
</thead>
<tbody>
<tr>
<td rowspan="3">Vacuolization of PT</td>
<td>0</td>
<td>No change</td>
</tr>
<tr>
<td>1</td>
<td>Clear increase in number and size of apical vacuoles</td>
</tr>
<tr>
<td>2</td>
<td>Obvious and widespread vacuoles</td>
</tr>
<tr>
<td rowspan="3">Epithelial sloughing of PT</td>
<td>0</td>
<td>No change</td>
</tr>
<tr>
<td>1</td>
<td>Loss of apical brushing borders</td>
</tr>
<tr>
<td>2</td>
<td>Obvious sloughing of tubular cells with debris in the tubular lumens</td>
</tr>
<tr>
<td rowspan="3">Epithelial thinning of PT</td>
<td>0</td>
<td>No change</td>
</tr>
<tr>
<td>1</td>
<td>More than half the height of normal PT cells</td>
</tr>
<tr>
<td>2</td>
<td>Less than half the height of normal PT cells</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn1-0960327112450897">
<p>PT: proximal tubule.</p>
</fn>
</table-wrap-foot>
</table-wrap>
</sec>
<sec id="section7-0960327112450897">
<title>Statistical analysis</title>
<p>Continuous variables were expressed as median (25th to 75th percentile). The differences in Ccr between baseline and 48 h after the gadodiamide infusion were compared using Wilcoxon’s signed-rank test. Comparisons of control and hydration groups were done using the Wilcoxon’s rank-sum test for the percentage of Ccr reduction and pathological weighted scores for renal tubular injury. Significance was set at <italic>p</italic> &lt; 0.05. SPSS for Windows 17.0 (SPSS Inc., Chicago, Illinois, USA) was used for all data analysis.</p>
</sec>
</sec>
<sec id="section8-0960327112450897">
<title>Results</title>
<sec id="section9-0960327112450897">
<title>Effect of saline hydration on renal function</title>
<p>There was no significant difference in baseline Ccr between the control and hydration groups. High-dose gadodiamide induced an acute deterioration of renal function revealed by significant reductions in Ccr from baseline in both the groups (control group: from baseline = 2.11 mL/min (1.96 mL/min, 2.22 mL/min) (data are median (25th to 75th percentile)) to 1.29 mL/min (1.23 mL/min, 1.38 mL/min) 48 h postinfusion (−39%; <italic>p</italic> = 0.02); hydration group: from baseline = 1.86 mL/min (1.57 mL/min, 2.19 mL/min) to 1.67 mL/min (1.36 mL/min, 2.86 mL/min) 48 h postinfusion (−15%; <italic>p</italic> = 0.04)) (<xref ref-type="fig" rid="fig1-0960327112450897">Figure 1</xref>(a) and (b)). The percentage deterioration of renal function in the control group was significantly higher than in the hydration group (<italic>p</italic> = 0.02).</p>
<fig id="fig1-0960327112450897" position="float">
<label>Figure 1.</label>
<caption>
<p>Ccr was lower after a gadodiamide-CM injection. Ccr was evaluated at baseline and 48 h after a gadodiamide-CM injection. (a) Gadodiamide-CM induced acute renal function deterioration in both the control and the hydration groups. (b) Prophylactic 0.9% saline hydration significantly inhibited the percentage of the reduction in Ccr. Data are means ± SD; *,†<italic>p</italic> &lt; 0.05 versus baseline, #<italic>p</italic> &lt; 0.05 versus control group. Ccr: creatinine clearance; CM: contrast medium.</p>
</caption>
<graphic alternate-form-of="fig1-0960327112450897" xlink:href="10.1177_0960327112450897-fig1.tif"/>
</fig>
</sec>
<sec id="section10-0960327112450897">
<title>Evaluation of renal histology</title>
<p>Morphological analysis of the kidney sections revealed renal proximal tubular injury in both the groups, but significant glomerular or vascular lesions were not found (<xref ref-type="fig" rid="fig2-0960327112450897">Figure 2</xref>). Furthermore, the tubular cell injuries characterized by vacuolization, loss of brush borders, sloughing of tubular cells into the lumen, and flattening of the tubular epithelium were less frequently seen in the hydration group.</p>
<fig id="fig2-0960327112450897" position="float">
<label>Figure 2.</label>
<caption>
<p>Pathological changes of the kidney 48 h after (a,b) a Gd-CM injection (control group) and (c,d) injection of Gd-CM plus 0.9% saline hydration (hydration group). The proximal tubules are widely vacuolated. The injured tubules (asterisks) show a loss of cell height and brush border with sloughed epithelial cells in the tubular lumen. Note that vacuolization and epithelial sloughing in the Hydration group occurred less frequently than in the control group. All figures show cells stained with hematoxylin and eosin; original magnifications are ×200 (a,c) and ×400 (b,d). Gd-CM: gadolinium-based contrast medium.</p>
</caption>
<graphic alternate-form-of="fig2-0960327112450897" xlink:href="10.1177_0960327112450897-fig2.tif"/>
</fig>
</sec>
<sec id="section11-0960327112450897">
<title>Proximal tubule vacuolization</title>
<p>In the control group, vacuolization was obvious and more prominent than in the hydration group. In most of the specimens, vacuoles also filled the region near the basal membrane (<xref ref-type="fig" rid="fig2-0960327112450897">Figure 2</xref>(a) and (b)). Most of the vacuolization scores were 1 and 2 (<xref ref-type="table" rid="table2-0960327112450897">Table 2</xref>). In the hydration group, sporadic vacuoles were seen, but the degree of vacuolization was significantly less than in the control group (<xref ref-type="fig" rid="fig2-0960327112450897">Figure 2</xref>(c) and (d); <xref ref-type="table" rid="table2-0960327112450897">Table 2</xref>). The weighted scores were significantly lower in the hydration group than in the control group (<italic>p</italic> = 0.01; <xref ref-type="fig" rid="fig3-0960327112450897">Figure 3</xref>(a)).</p>
<fig id="fig3-0960327112450897" position="float">
<label>Figure 3.</label>
<caption>
<p>Weighted scores for renal tubular injury after a Gd-CM injection: (a) vacuolization score of PT; (b) epithelial sloughing score for PT; and (c) epithelial thinning score of PT. Results are means ± SD. *<italic>p</italic> &lt; 0.05 versus control group. Gd-CM: gadolinium-based contrast medium; PT: proximal tubules.</p>
</caption>
<graphic alternate-form-of="fig3-0960327112450897" xlink:href="10.1177_0960327112450897-fig3.tif"/>
</fig>
<table-wrap id="table2-0960327112450897" position="float">
<label>Table 2.</label>
<caption>
<p>Weighted scores for cytoplasmic vacuolization, epithelial sloughing, and epithelial thinning after a Gd-CM injection in the control and hydrated groups</p>
</caption>
<graphic alternate-form-of="table2-0960327112450897" xlink:href="10.1177_0960327112450897-table2.tif"/>
<table>
<thead>
<tr>
<th rowspan="2">Group</th>
<th rowspan="2">No.</th>
<th colspan="4">Vacuolization</th>
<th colspan="4">Epithelial sloughing</th>
<th colspan="4">Epithelial thinning</th>
</tr>
<tr>
<th>0</th>
<th>1</th>
<th>2</th>
<th>Weighted score</th>
<th>0</th>
<th>1</th>
<th>2</th>
<th>Weighted score</th>
<th>0</th>
<th>1</th>
<th>2</th>
<th>Weighted score</th>
</tr>
</thead>
<tbody>
<tr>
<td rowspan="6">Control</td>
<td>1</td>
<td>11</td>
<td>48</td>
<td>41</td>
<td>130</td>
<td>10</td>
<td>20</td>
<td>70</td>
<td>160</td>
<td>51</td>
<td>38</td>
<td>11</td>
<td>60</td>
</tr>
<tr>
<td>2</td>
<td>33</td>
<td>44</td>
<td>23</td>
<td>90</td>
<td>21</td>
<td>48</td>
<td>31</td>
<td>110</td>
<td>41</td>
<td>53</td>
<td>6</td>
<td>65</td>
</tr>
<tr>
<td>3</td>
<td>12</td>
<td>46</td>
<td>32</td>
<td>110</td>
<td>13</td>
<td>24</td>
<td>63</td>
<td>150</td>
<td>41</td>
<td>44</td>
<td>13</td>
<td>70</td>
</tr>
<tr>
<td>4</td>
<td>11</td>
<td>18</td>
<td>71</td>
<td>160</td>
<td>11</td>
<td>18</td>
<td>71</td>
<td>160</td>
<td>42</td>
<td>46</td>
<td>22</td>
<td>90</td>
</tr>
<tr>
<td>5</td>
<td>11</td>
<td>28</td>
<td>61</td>
<td>150</td>
<td>2</td>
<td>26</td>
<td>72</td>
<td>170</td>
<td>23</td>
<td>54</td>
<td>23</td>
<td>100</td>
</tr>
<tr>
<td>6</td>
<td>20</td>
<td>20</td>
<td>60</td>
<td>140</td>
<td>12</td>
<td>36</td>
<td>52</td>
<td>140</td>
<td>50</td>
<td>40</td>
<td>10</td>
<td>60</td>
</tr>
<tr>
<td rowspan="6">Hydration</td>
<td>1</td>
<td>60</td>
<td>30</td>
<td>10</td>
<td>50</td>
<td>60</td>
<td>35</td>
<td>5</td>
<td>45</td>
<td>60</td>
<td>35</td>
<td>5</td>
<td>45</td>
</tr>
<tr>
<td>2</td>
<td>51</td>
<td>38</td>
<td>11</td>
<td>60</td>
<td>17</td>
<td>71</td>
<td>12</td>
<td>95</td>
<td>71</td>
<td>18</td>
<td>11</td>
<td>40</td>
</tr>
<tr>
<td>3</td>
<td>40</td>
<td>55</td>
<td>5</td>
<td>65</td>
<td>32</td>
<td>54</td>
<td>13</td>
<td>80</td>
<td>61</td>
<td>33</td>
<td>6</td>
<td>45</td>
</tr>
<tr>
<td>4</td>
<td>28</td>
<td>54</td>
<td>18</td>
<td>90</td>
<td>22</td>
<td>64</td>
<td>13</td>
<td>90</td>
<td>24</td>
<td>52</td>
<td>24</td>
<td>100</td>
</tr>
<tr>
<td>5</td>
<td>13</td>
<td>64</td>
<td>23</td>
<td>110</td>
<td>32</td>
<td>46</td>
<td>22</td>
<td>90</td>
<td>33</td>
<td>44</td>
<td>23</td>
<td>90</td>
</tr>
<tr>
<td>6</td>
<td>32</td>
<td>48</td>
<td>22</td>
<td>92</td>
<td>51</td>
<td>28</td>
<td>21</td>
<td>70</td>
<td>51</td>
<td>38</td>
<td>11</td>
<td>60</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn2-0960327112450897">
<p>Gd-CM: gadolinium-based contrast medium.</p>
</fn>
</table-wrap-foot>
</table-wrap>
</sec>
<sec id="section12-0960327112450897">
<title>Proximal tubule sloughing</title>
<p>Renal tubular epithelial cell damage, observed as cellular degeneration and sloughing from tubular basement membranes, was seen after a high-dose gadodiamide infusion (<xref ref-type="fig" rid="fig2-0960327112450897">Figure 2</xref>). Damage was most often localized in the proximal tubular epithelia. In the control group, the lumens of numerous <italic>tubules</italic> contained <italic>sloughed epithelial</italic> cells and cellular debris. Most of the scores for epithelial sloughing were 3 (<xref ref-type="table" rid="table2-0960327112450897">Table 2</xref>). In the hydration group, the degenerative change was much less than in the control group; most of the scores in the hydration group were 0 or 1 (<xref ref-type="table" rid="table2-0960327112450897">Table 2</xref>). The difference between the two groups was significant (<italic>p</italic> = 0.02; <xref ref-type="fig" rid="fig3-0960327112450897">Figure 3</xref>(b)).</p>
</sec>
<sec id="section13-0960327112450897">
<title>Proximal tubule thinning</title>
<p>The injured tubules show a loss of brush borders and a reduction in tubular cell height (<xref ref-type="fig" rid="fig2-0960327112450897">Figure 2</xref>). However, the difference in the extent of epithelial thinning of the proximal tubules between the two groups was not significant.</p>
</sec>
</sec>
<sec id="section14-0960327112450897">
<title>Discussion</title>
<p>We found that high-dose gadodiamide is nephrotoxic in rats. Morphological analysis disclosed typical CIN pathologic changes. We also found that prophylactic 0.9% saline hydration helped to protect renal function by partially inhibiting histological damage (vacuolization and epithelial sloughing) in high-dose gadodiamide-induced nephropathy rats.</p>
<p>The pathogenesis of iodinated CM-induced nephropathy is associated with alterations in renal hemodynamics (ischemia due to vasoconstriction), reactions to hyperosmolar agents, and direct tubular toxicity.<sup>
<xref ref-type="bibr" rid="bibr27-0960327112450897">27</xref>
</sup> The cytotoxic effects induced by iodinated CM are osmolality-dependent.<sup>
<xref ref-type="bibr" rid="bibr10-0960327112450897">10</xref>,<xref ref-type="bibr" rid="bibr22-0960327112450897">22</xref>,<xref ref-type="bibr" rid="bibr28-0960327112450897">28</xref>
</sup> Gd-based CMs are also hypertonic, with an osmolarity of two to seven times greater than that of plasma, and they are not absorbed by renal tubular epithelial cells. These characteristics of Gd chelates are similar to those of iodinated CM. The injection of high-dose of gadodiamide could result in a substantial osmotic load to the kidneys. High osmolar CM induce intense and prolonged vasoconstriction at the corticomedullary junction of the kidneys and directly impairs the autoregulatory ability of the kidneys.<sup>
<xref ref-type="bibr" rid="bibr1-0960327112450897">1</xref>,<xref ref-type="bibr" rid="bibr29-0960327112450897">29</xref><xref ref-type="bibr" rid="bibr30-0960327112450897"/><xref ref-type="bibr" rid="bibr31-0960327112450897"/><xref ref-type="bibr" rid="bibr32-0960327112450897"/><xref ref-type="bibr" rid="bibr33-0960327112450897"/><xref ref-type="bibr" rid="bibr34-0960327112450897"/>–<xref ref-type="bibr" rid="bibr35-0960327112450897">35</xref></sup>
</p>
<p>Several agents are suggested as beneficial for preventing CIN: hydration, <italic>N</italic>-acetylcysteine, furosemide, mannitol, dopamine hydrochloride, aminophylline, and arterial natriuretic peptide. Among these, hydration is the most widely accepted and recommended.<sup>
<xref ref-type="bibr" rid="bibr2-0960327112450897">2</xref>
</sup> It may be that the predominant mechanism of CIN is the alteration of renal hemodynamics, and that hydration counteracts this action.<sup>
<xref ref-type="bibr" rid="bibr1-0960327112450897">1</xref>,<xref ref-type="bibr" rid="bibr2-0960327112450897">2</xref>
</sup> Volume supplementation causes plasma volume to expand and concomitantly suppresses the rennin–angiotensin–aldosterone system, downregulates tubuloglomerular feedback, dilutes the CM, and, thus, prevents renal cortical vasoconstriction, medullary ischemia, and tubular obstruction.<sup>
<xref ref-type="bibr" rid="bibr1-0960327112450897">1</xref>,<xref ref-type="bibr" rid="bibr33-0960327112450897">33</xref>
</sup>
</p>
<p>Although the benefits of hydration for preventing iodinated CM-induced nephropathy are well documented, there are only limited data available on the preventive effects of hydration in patients with Gd-CM-induced nephropathy. In a prospective, randomized, controlled pilot study,<sup>
<xref ref-type="bibr" rid="bibr16-0960327112450897">16</xref>
</sup> 21 patients given Gd-CM or iodinated CM were intravenously hydrated with 1000 mL of fluid 12 h before and 12 h after CM administration. The incidence of CIN was similar in the both groups. In a retrospective study<sup>
<xref ref-type="bibr" rid="bibr36-0960327112450897">36</xref>
</sup> of 25 patients given Gd-CM for coronary procedures and 32 patients given iodinated CM, all patients had been intravenously hydrated at a rate of 1 mL/kg/h from 12 h before to 12 h after they had been given CM and <italic>n</italic>-acetylcysteine. The rate of CIN did not differ between the Gd-CM and iodinated CM groups; hydration had not reduced the incidence of Gd-CM-induced nephropathy, and the effect of hydration was not significant between patients given iodinated CM and Gd-CM.</p>
<p>Histological data from a limited number of animal studies<sup>
<xref ref-type="bibr" rid="bibr12-0960327112450897">12</xref>,<xref ref-type="bibr" rid="bibr22-0960327112450897">22</xref>,<xref ref-type="bibr" rid="bibr37-0960327112450897">37</xref>
</sup> suggest that Gd-CM acutely injures the epithelial cells of the renal tubules. A large dose of Gd-CM induced significant cytoplasmic vacuolization in proximal convoluted tubular cells, and the pathologic change was intensified by dehydration.<sup>
<xref ref-type="bibr" rid="bibr37-0960327112450897">37</xref>,<xref ref-type="bibr" rid="bibr38-0960327112450897">38</xref>
</sup> Till date, there are few reports on the renal lesions associated with Gd-CM-induced nephropathy in humans. One 56-year-old patient with diabetes developed acute renal failure after being given Gd-CM in two consecutive vascular imaging procedures to explore a hypertensive crisis.<sup>
<xref ref-type="bibr" rid="bibr18-0960327112450897">18</xref>
</sup> A kidney biopsy showed acute tubular cell injury, which included patchy tubular necrosis, tubular epithelial cell degeneration, and marked proliferation of tubular cells, together with mild interstitial edema and infiltration. In our study, renal tubular vacuolization, tubular epithelial sloughing, and tubular epithelial thinning were seen after a single high dose of intravenous gadodiamide. In the hydration group, cortical tubular cell injuries induced by high-dose gadodiamide were seen less frequently than in the control group. Vacuolization and epithelial sloughing of the proximal tubules differed significantly between the two groups. Tubular vacuolization is seen following the infusion of hypertonic solutions. Tubular epithelial sloughing reflects the death of tubular cells, which are then sloughed into the lumen. These two changes are predominant during acute kidney injury. However, proximal tubular thinning represents regenerative change, which is more apparent during the recovery phase but not during acute kidney injury.<sup>
<xref ref-type="bibr" rid="bibr39-0960327112450897">39</xref>
</sup> Therefore, there were no changes in proximal tubule thinning in the acute stage.</p>
<p>Developing Gd-CM-induced nephropathy is related to preexisting risk factors such as diabetes mellitus and renal insufficiency.<sup>
<xref ref-type="bibr" rid="bibr17-0960327112450897">17</xref>,<xref ref-type="bibr" rid="bibr19-0960327112450897">19</xref>
</sup> Patients with diabetes mellitus are more likely to develop CIN because of their impaired baseline renal blood flow. However, an immediate decrease in renal blood flow does not occur in well-hydrated patients exposed to CM.<sup>
<xref ref-type="bibr" rid="bibr40-0960327112450897">40</xref>
</sup> Low-dose Gd-CM seems to be well tolerated. In contrast, patients with renal insufficiency given higher doses (&gt;0.3–0.4 mmol/kg BW) experience greater nephropathy.<sup>
<xref ref-type="bibr" rid="bibr8-0960327112450897">8</xref>
</sup>
</p>
<p>Our study is limited by its lack of other well-documented biomarkers to support the benefits of hydration therapy, for example, checking and comparing neutrophil gelatinase-associated lipocalin in urine, cystatin C in blood, or immunochemical staining for kidney injury molecule-1 on kidney samples, which may bring more confidence. Because the study also lacks some biochemical tests—glucose, urea, total cholesterol, triglycerides, and low-density lipoprotein cholesterol in blood and urine—we do not have sufficient data for broad and firm conclusions. Second, hydration is beneficial when combined with high-dose Gd-CM, but it may not give significant benefits for lower, clinically used doses of Gd-CM.</p>
<p>Intravenous high-dose gadodiamide induced acute renal damage in Sprague-Dawley rats. We showed that prophylactic 0.9% saline hydration helped prevent functional and histological abnormalities in rats administered with a high dose of gadodiamide. Preventive hydration therapy is a simple and effective measure and should be considered for humans given high-dose gadodiamide, especially patients at high risk of acute kidney injury.</p>
</sec>
</body>
<back>
<fn-group>
<fn fn-type="financial-disclosure" id="fn1-0960327112450897"><label>Authors’ Note</label><p>Chih-Chiang Chien and Ming-Jen Sheu contributed equally to this work.</p></fn>
<fn fn-type="financial-disclosure" id="fn2-0960327112450897"><label>Funding</label>
<p>This study was supported by grant CMFHR9766 from the Chi-Mei Medical Center.</p></fn>
</fn-group>
<ack>
<title>Acknowledgments</title>
<p>The authors thank all the staffs in Professor Jhi-Joung Wang’s Department of Medical Research.</p>
</ack>
<ref-list>
<title>References</title>
<ref id="bibr1-0960327112450897">
<label>1.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Solomon</surname>
<given-names>R</given-names>
</name>
</person-group>. <article-title>Contrast-medium-induced acute renal failure</article-title>. <source>Kidney Int</source> <year>1998</year>; <volume>53</volume>: <fpage>230</fpage>–<lpage>242</lpage>.</citation>
</ref>
<ref id="bibr2-0960327112450897">
<label>2.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Barrett</surname>
<given-names>BJ</given-names>
</name>
<name>
<surname>Parfrey</surname>
<given-names>PS</given-names>
</name>
</person-group>. <article-title>Preventing nephropathy induced by contrast medium</article-title>. <source>N Engl J Med</source> <year>2006</year>; <volume>354</volume>: <fpage>379</fpage>–<lpage>386</lpage>.</citation>
</ref>
<ref id="bibr3-0960327112450897">
<label>3.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nash</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Hafeez</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Hou</surname>
<given-names>S</given-names>
</name>
</person-group>. <article-title>Hospital-acquired renal insufficiency</article-title>. <source>Am J Kidney Dis</source> <year>2002</year>; <volume>39</volume>: <fpage>930</fpage>–<lpage>936</lpage>.</citation>
</ref>
<ref id="bibr4-0960327112450897">
<label>4.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kaufman</surname>
<given-names>JA</given-names>
</name>
<name>
<surname>Geller</surname>
<given-names>SC</given-names>
</name>
<name>
<surname>Waltman</surname>
<given-names>AC</given-names>
</name>
</person-group>. <article-title>Renal insufficiency: gadopentetate dimeglumine as a radiographic contrast agent during peripheral vascular interventional procedures</article-title>. <source>Radiology</source> <year>1996</year>; <volume>198</volume>: <fpage>579</fpage>–<lpage>581</lpage>.</citation>
</ref>
<ref id="bibr5-0960327112450897">
<label>5.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Spinosa</surname>
<given-names>DJ</given-names>
</name>
<name>
<surname>Matsumoto</surname>
<given-names>AH</given-names>
</name>
<name>
<surname>Angle</surname>
<given-names>JF</given-names>
</name>
<name>
<surname>Hagspiel</surname>
<given-names>KD</given-names>
</name>
</person-group>. <article-title>Use of gadopentetate dimeglumine as a contrast agent for percutaneous transluminal renal angioplasty and stent placement</article-title>. <source>Kidney Int</source> <year>1998</year>; <volume>53</volume>: <fpage>503</fpage>–<lpage>507</lpage>.</citation>
</ref>
<ref id="bibr6-0960327112450897">
<label>6.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Prince</surname>
<given-names>MR</given-names>
</name>
<name>
<surname>Arnoldus</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Frisoli</surname>
<given-names>JK</given-names>
</name>
</person-group>. <article-title>Nephrotoxicity of high dose gadolinium compared with iodinated contrast</article-title>. <source>J Magn Reson Imaging</source> <year>1996</year>; <volume>6</volume>: <fpage>162</fpage>–<lpage>166</lpage>.</citation>
</ref>
<ref id="bibr7-0960327112450897">
<label>7.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bellin</surname>
<given-names>MF</given-names>
</name>
<name>
<surname>Deray</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Assogba</surname>
<given-names>U</given-names>
</name>
<name>
<surname>Auberton</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Ghany</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Dion-Voirin</surname>
<given-names>E</given-names>
</name>
<etal/>
</person-group> <article-title>Gd-DOTA: evaluation of its renal tolerance in patients with chronic renal failure</article-title>. <source>Magn Reson Imaging</source> <year>1992</year>; <volume>10</volume>: <fpage>115</fpage>–<lpage>118</lpage>.</citation>
</ref>
<ref id="bibr8-0960327112450897">
<label>8.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nyman</surname>
<given-names>U</given-names>
</name>
<name>
<surname>Elmståhl</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Leander</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Nilsson</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Golman</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Almén</surname>
<given-names>T</given-names>
</name>
</person-group>. <article-title>Are gadolinium-based contrast media really safer than iodinated media for digital subtraction angiography in patients with azotemia?</article-title> <source>Radiology</source> <year>2002</year>; <volume>223</volume>: <fpage>311</fpage>–<lpage>318</lpage>.</citation>
</ref>
<ref id="bibr9-0960327112450897">
<label>9.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Elmståhl</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Nyman</surname>
<given-names>U</given-names>
</name>
<name>
<surname>Leander</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Chai</surname>
<given-names>CM</given-names>
</name>
<name>
<surname>Frennby</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Almén</surname>
<given-names>T</given-names>
</name>
</person-group>. <article-title>Gadolinium contrast media are more nephrotoxic than a low osmolar iodine medium employing doses with equal x-ray attenuation in renal arteriography: an experimental study in pigs</article-title>. <source>Acad Radiol</source> <year>2004</year>; <volume>11</volume>: <fpage>1219</fpage>–<lpage>1228</lpage>.</citation>
</ref>
<ref id="bibr10-0960327112450897">
<label>10.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Elmståhl</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Nyman</surname>
<given-names>U</given-names>
</name>
<name>
<surname>Leander</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Chai</surname>
<given-names>CM</given-names>
</name>
<name>
<surname>Golman</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Björk</surname>
<given-names>J</given-names>
</name>
<etal/>
</person-group> <article-title>Gadolinium contrast media are more nephrotoxic than iodine media. The importance of osmolality in direct renal artery injections</article-title>. <source>Eur Radiol</source> <year>2006</year>; <volume>16</volume>: <fpage>2712</fpage>–<lpage>2720</lpage>.</citation>
</ref>
<ref id="bibr11-0960327112450897">
<label>11.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Boyden</surname>
<given-names>TF</given-names>
</name>
<name>
<surname>Gurm</surname>
<given-names>HS</given-names>
</name>
</person-group>. <article-title>Does gadolinium-based angiography protect against contrast-induced nephropathy?</article-title> <source>Catheter Cardiovasc Interv</source> <year>2008</year>; <volume>71</volume>: <fpage>687</fpage>–<lpage>693</lpage>.</citation>
</ref>
<ref id="bibr12-0960327112450897">
<label>12.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Elmståhl</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Nyman</surname>
<given-names>U</given-names>
</name>
<name>
<surname>Leander</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Golman</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Chai</surname>
<given-names>CM</given-names>
</name>
<name>
<surname>Grant</surname>
<given-names>D</given-names>
</name>
<etal/>
</person-group> <article-title>Iodixanol 320 results in better renal tolerance and radiodensity than do gadolinium-based contrast media: arteriography in ischemic porcine kidneys</article-title>. <source>Radiology</source> <year>2008</year>; <volume>247</volume>: <fpage>88</fpage>–<lpage>97</lpage>.</citation>
</ref>
<ref id="bibr13-0960327112450897">
<label>13.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Halvorsen</surname>
<given-names>RA</given-names>
</name>
</person-group>. <article-title>Which study when? Iodinated contrast-enhanced CT versus gadolinium-enhanced MR imaging</article-title>. <source>Radiology</source> <year>2008</year>; <volume>249</volume>: <fpage>9</fpage>–<lpage>15</lpage>.</citation>
</ref>
<ref id="bibr14-0960327112450897">
<label>14.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gemery</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Idelson</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Reid</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Yucel</surname>
<given-names>EK</given-names>
</name>
<name>
<surname>Pagan-Marin</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Ali</surname>
<given-names>S</given-names>
</name>
<etal/>
</person-group> <article-title>Acute renal failure after arteriography with a gadolinium-based contrast agent</article-title>. <source>Am J Roentgenol</source> <year>1998</year>; <volume>171</volume>: <fpage>1277</fpage>–<lpage>1278</lpage>.</citation>
</ref>
<ref id="bibr15-0960327112450897">
<label>15.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Thomsen</surname>
<given-names>HS</given-names>
</name>
</person-group>. <article-title>Gadolinium-based contrast media may be nephrotoxic even at approved doses</article-title>. <source>Eur Radiol</source> <year>2004</year>; <volume>14</volume>: <fpage>1654</fpage>–<lpage>1656</lpage>.</citation>
</ref>
<ref id="bibr16-0960327112450897">
<label>16.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Erley</surname>
<given-names>CM</given-names>
</name>
<name>
<surname>Bader</surname>
<given-names>BD</given-names>
</name>
<name>
<surname>Berger</surname>
<given-names>ED</given-names>
</name>
<name>
<surname>Tuncel</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Winkler</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Tepe</surname>
<given-names>G</given-names>
</name>
<etal/>
</person-group> <article-title>Gadolinium-based contrast media compared with iodinated media for digital subtraction angiography in azotaemic patients</article-title>. <source>Nephrol Dial Transplant</source> <year>2004</year>; <volume>19</volume>: <fpage>2526</fpage>–<lpage>2531</lpage>.</citation>
</ref>
<ref id="bibr17-0960327112450897">
<label>17.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ergün</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Keven</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Uruç</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Ekmekçi</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Canbakan</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Erden</surname>
<given-names>I</given-names>
</name>
<etal/>
</person-group> <article-title>The safety of gadolinium in patients with stage 3 and 4 renal failure</article-title>. <source>Nephrol Dial Transplant</source> <year>2006</year>; <volume>21</volume>: <fpage>697</fpage>–<lpage>700</lpage>.</citation>
</ref>
<ref id="bibr18-0960327112450897">
<label>18.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Akgun</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Gonlusen</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Cartwright</surname>
<given-names>J</given-names>
<suffix>Jr.</suffix>
</name>
<name>
<surname>Suki</surname>
<given-names>WN</given-names>
</name>
<name>
<surname>Truong</surname>
<given-names>LD</given-names>
</name>
</person-group>. <article-title>Are gadolinium-based contrast media nephrotoxic? A renal biopsy study</article-title>. <source>Arch Pathol Lab Med</source> <year>2006</year>; <volume>130</volume>: <fpage>1354</fpage>–<lpage>1357</lpage>.</citation>
</ref>
<ref id="bibr19-0960327112450897">
<label>19.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sam</surname>
<given-names>AD</given-names>
<suffix>2nd</suffix>
</name>
<name>
<surname>Morasch</surname>
<given-names>MD</given-names>
</name>
<name>
<surname>Collins</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Song</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Pereles</surname>
<given-names>FS</given-names>
</name>
</person-group>. <article-title>Safety of gadolinium contrast angiography in patients with chronic renal insufficiency</article-title>. <source>J Vasc Surg</source> <year>2003</year>; <volume>38</volume>: <fpage>313</fpage>–<lpage>318</lpage>.</citation>
</ref>
<ref id="bibr20-0960327112450897">
<label>20.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Thomsen</surname>
<given-names>HS</given-names>
</name>
<name>
<surname>Almèn</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Morcos</surname>
<given-names>SK</given-names>
</name>
</person-group>; <collab collab-type="author">Contrast media safety committee of the European society of urogenital radiology (ESUR)</collab>. <article-title>Gadolinium-containing contrast media for radiographic examinations: a position paper</article-title>. <source>Eur Radiol</source> <year>2002</year>; <volume>12</volume>: <fpage>2600</fpage>–<lpage>2605</lpage>.</citation>
</ref>
<ref id="bibr21-0960327112450897">
<label>21.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Becker</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Thompson</surname>
<given-names>H</given-names>
</name>
</person-group>. <article-title>Renal safety of gadolinium-based contrast agent for ionizing radiation imaging</article-title>. <source>Radiology</source> <year>2006</year>; <volume>240</volume>: <fpage>301</fpage>–<lpage>302</lpage>.</citation>
</ref>
<ref id="bibr22-0960327112450897">
<label>22.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Heinrich</surname>
<given-names>MC</given-names>
</name>
<name>
<surname>Kuhlmann</surname>
<given-names>MK</given-names>
</name>
<name>
<surname>Kohlbacher</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Scheer</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Grgic</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Heckmann</surname>
<given-names>MB</given-names>
</name>
<etal/>
</person-group> <article-title>Cytotoxicity of iodinated and gadolinium-based contrast agents in renal tubular cells at angiographic concentrations: in vitro study</article-title>. <source>Radiology</source> <year>2007</year>; <volume>242</volume>: <fpage>425</fpage>–<lpage>434</lpage>.</citation>
</ref>
<ref id="bibr23-0960327112450897">
<label>23.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Buhaescu</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Izzedine</surname>
<given-names>H</given-names>
</name>
</person-group>. <article-title>Gadolinium-induced nephrotoxicity</article-title>. <source>Int J Clin Pract</source> <year>2008</year>; <volume>62</volume>: <fpage>1113</fpage>–<lpage>1118</lpage>.</citation>
</ref>
<ref id="bibr24-0960327112450897">
<label>24.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Weinreb</surname>
<given-names>JC</given-names>
</name>
</person-group>. <article-title>Which study when? Is gadolinium-enhanced MR imaging safer than iodine-enhanced CT?</article-title> <source>Radiology</source> <year>2008</year>; <volume>249</volume>: <fpage>3</fpage>–<lpage>8</lpage>.</citation>
</ref>
<ref id="bibr25-0960327112450897">
<label>25.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Harpur</surname>
<given-names>ES</given-names>
</name>
<name>
<surname>Worah</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Hals</surname>
<given-names>PA</given-names>
</name>
<name>
<surname>Holtz</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Furuhama</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Nomura</surname>
<given-names>H</given-names>
</name>
</person-group>. <article-title>Preclinical safety assessment and pharmacokinetics of gadodiamide injection, a new magnetic resonance imaging contrast agent</article-title>. <source>Invest Radiol</source> <year>1993</year>; <volume>28</volume> (<issue>Suppl 1</issue>): <fpage>S28</fpage>–<lpage>S43</lpage>.</citation>
</ref>
<ref id="bibr26-0960327112450897">
<label>26.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Thomsen</surname>
<given-names>HS</given-names>
</name>
<name>
<surname>Dorph</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Larsen</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Horn</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Hemmingsen</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Skaarup</surname>
<given-names>P</given-names>
</name>
<etal/>
</person-group> <article-title>Urine profiles and kidney histology after intravenous injection of ionic and nonionic radiologic and magnetic resonance contrast media in normal rats</article-title>. <source>Acad Radiol</source> <year>1994</year>; <volume>1</volume>: <fpage>128</fpage>–<lpage>135</lpage>.</citation>
</ref>
<ref id="bibr27-0960327112450897">
<label>27.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Brezis</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Rosen</surname>
<given-names>S</given-names>
</name>
</person-group>. <article-title>Hypoxia of the renal medulla—its implications for disease</article-title>. <source>N Engl J Med</source> <year>1995</year>; <volume>332</volume>: <fpage>647</fpage>–<lpage>655</lpage>.</citation>
</ref>
<ref id="bibr28-0960327112450897">
<label>28.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ledneva</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Karie</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Launay-Vacher</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Janus</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Deray</surname>
<given-names>G</given-names>
</name>
</person-group>. <article-title>Renal safety of gadolinium-based contrast media in patients with chronic renal insufficiency</article-title>. <source>Radiology</source> <year>2009</year>; <volume>250</volume>: <fpage>618</fpage>–<lpage>628</lpage>.</citation>
</ref>
<ref id="bibr29-0960327112450897">
<label>29.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Katholi</surname>
<given-names>RE</given-names>
</name>
<name>
<surname>Woods</surname>
<given-names>WT</given-names>
<suffix>Jr.</suffix>
</name>
<name>
<surname>Taylor</surname>
<given-names>GJ</given-names>
</name>
<name>
<surname>Deitrick</surname>
<given-names>CL</given-names>
</name>
<name>
<surname>Womack</surname>
<given-names>KA</given-names>
</name>
<name>
<surname>Katholi</surname>
<given-names>CR</given-names>
</name>
<etal/>
</person-group> <article-title>Oxygen free radicals and contrast nephropathy</article-title>. <source>Am J Kidney Dis</source> <year>1998</year>; <volume>32</volume>: <fpage>64</fpage>–<lpage>71</lpage>.</citation>
</ref>
<ref id="bibr30-0960327112450897">
<label>30.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Heyman</surname>
<given-names>SN</given-names>
</name>
<name>
<surname>Reichman</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Brezis</surname>
<given-names>M</given-names>
</name>
</person-group>. <article-title>Pathophysiology of radiocontrast nephropathy: a role for medullary hypoxia</article-title>. <source>Invest Radiol</source> <year>1999</year>; <volume>34</volume>: <fpage>685</fpage>–<lpage>691</lpage>.</citation>
</ref>
<ref id="bibr31-0960327112450897">
<label>31.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Persson</surname>
<given-names>PB</given-names>
</name>
<name>
<surname>Patzak</surname>
<given-names>A</given-names>
</name>
</person-group>. <article-title>Renal haemodynamic alterations in contrast medium-induced nephropathy and the benefit of hydration</article-title>. <source>Nephrol Dial Transplant</source> <year>2005</year>; <volume>20</volume> (<issue>Suppl 1</issue>): <fpage>2</fpage>–<lpage>5</lpage>.</citation>
</ref>
<ref id="bibr32-0960327112450897">
<label>32.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tumlin</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Stacul</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Adam</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Becker</surname>
<given-names>CR</given-names>
</name>
<name>
<surname>Davidson</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Lameire</surname>
<given-names>N</given-names>
</name>
<etal/>
</person-group> <article-title>Pathophysiology of contrast-induced nephropathy</article-title>. <source>Am J Cardiol</source> <year>2006</year>; <volume>98</volume>: <fpage>14K</fpage>–<lpage>20K</lpage>.</citation>
</ref>
<ref id="bibr33-0960327112450897">
<label>33.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Murphy</surname>
<given-names>SW</given-names>
</name>
<name>
<surname>Barrett</surname>
<given-names>BJ</given-names>
</name>
<name>
<surname>Parfrey</surname>
<given-names>PS</given-names>
</name>
</person-group>. <article-title>Contrast nephropathy</article-title>. <source>J Am Soc Nephrol</source> <year>2000</year>; <volume>11</volume>: <fpage>177</fpage>–<lpage>182</lpage>.</citation>
</ref>
<ref id="bibr34-0960327112450897">
<label>34.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Trivedi</surname>
<given-names>HS</given-names>
</name>
<name>
<surname>Moore</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Nasr</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Aggarwal</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Agrawal</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Goel</surname>
<given-names>P</given-names>
</name>
<etal/>
</person-group> <article-title>A randomized prospective trial to assess the role of saline hydration on the development of contrast nephrotoxicity</article-title>. <source>Nephron Clin Pract</source> <year>2003</year>; <volume>93</volume>: <fpage>C29</fpage>–<lpage>C34</lpage>.</citation>
</ref>
<ref id="bibr35-0960327112450897">
<label>35.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bader</surname>
<given-names>BD</given-names>
</name>
<name>
<surname>Berger</surname>
<given-names>ED</given-names>
</name>
<name>
<surname>Heede</surname>
<given-names>MB</given-names>
</name>
<name>
<surname>Silberbaur</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Duda</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Risler</surname>
<given-names>T</given-names>
</name>
<etal/>
</person-group> <article-title>What is the best hydration regimen to prevent contrast media-induced nephrotoxicity?</article-title> <source>Clin Nephrol</source> <year>2004</year>; <volume>62</volume>: <fpage>1</fpage>–<lpage>7</lpage>.</citation>
</ref>
<ref id="bibr36-0960327112450897">
<label>36.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Briguori</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Colombo</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Airoldi</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Melzi</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Michev</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Carlino</surname>
<given-names>M</given-names>
</name>
<etal/>
</person-group> <article-title>Gadolinium-based contrast agents and nephrotoxicity in patients undergoing coronary artery procedures</article-title>. <source>Catheter Cardiovasc Interv</source> <year>2006</year>; <volume>67</volume>: <fpage>175</fpage>–<lpage>180</lpage>.</citation>
</ref>
<ref id="bibr37-0960327112450897">
<label>37.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tervahartiala</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Kivisaari</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Kivisaari</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Virtanen</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Standertskjöld-Nordenstam</surname>
<given-names>CG</given-names></name></person-group>. <article-title>Contrast media-induced renal tubular vacuolization. A light and electron microscopic study on rat kidneys</article-title>. <source>Invest Radiol</source> <year>1991</year>; <volume>26</volume>: <fpage>882</fpage>–<lpage>887</lpage>.</citation>
</ref>
<ref id="bibr38-0960327112450897">
<label>38.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tervahartiala</surname>
<given-names>P</given-names>
</name>
</person-group>. <article-title>Contrast media-induced renal tubular vacuolization after dehydration. A light and electron microscopic study in rats</article-title>. <source>Invest Radiol</source> <year>1992</year>; <volume>27</volume>: <fpage>114</fpage>–<lpage>118</lpage>.</citation>
</ref>
<ref id="bibr39-0960327112450897">
<label>39.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Racusen</surname>
<given-names>LC</given-names>
</name>
<name>
<surname>Solez</surname>
<given-names>K</given-names>
</name>
</person-group>. <article-title>Nephrotoxic tubular and interstitial lesions: morphology and classification</article-title>. <source>Toxicol Pathol</source> <year>1986</year>; <volume>14</volume>: <fpage>45</fpage>–<lpage>57</lpage>.</citation>
</ref>
<ref id="bibr40-0960327112450897">
<label>40.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Weisberg</surname>
<given-names>LS</given-names>
</name>
<name>
<surname>Kurnik</surname>
<given-names>PB</given-names>
</name>
<name>
<surname>Kurnik</surname>
<given-names>BR</given-names>
</name>
</person-group>. <article-title>Risk of radiocontrast nephropathy in patients with and without diabetes mellitus</article-title>. <source>Kidney Int</source> <year>1994</year>; <volume>45</volume>: <fpage>259</fpage>–<lpage>265</lpage>.</citation>
</ref>
</ref-list>
</back>
</article>